Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF Five Reasons Sacubitril/Valsartan Should NOT Be Approved for HFpEF

The pricey drug Entresto is approved for heart failure with reduced ejection fraction, but should it also get an indication for HF with preserved ejection fraction? Cardiologist John Mandrola, MD, says no.theheart.org on Medscape
Source: Medscape Cardiology Headlines - Category: Cardiology Tags: Cardiology Expert Column Source Type: news